The Value Of~18F-FDG PET/CT In Evaluation Of Curative Effect And Prognostic On Lymphoma

Objective:To evaluate the value of F-FDG PET/CT in evaluation of curative effect,clinical staging and prognostic on Lymphoma after four or six cycles of chemotherapy for lymphoma (HL/NHL)patients. Methods:The data of85HL/NHL patients were retrospectively analyzed between November2008and February2014. All patients underwent standard therapy.After four or eight cycles the patients were evaluated with18F-FDG PET/CT.. Compare two years progression-free surial and oerall surial two years,The curative effect, clinical staging, and prognostic value of18F-FDG. PET/CT in HL/NHL was analyzed. Results:After four or six cycles the patients were evaluated with18F-FDG PET/CT,Treatment failure was seen in8of the12PET/CT-positive patients and in only4of the53PET/CT-negative patients. The treatment failure rate in PET/CT-positive patients was significantly higher than in the PET/CT-negative ones (P<0.01). The two-year PFS was40.2%for PET/CT-positive patients and89.7%for PET/CT-negative ones (P<0.01). Univariate survival analysis revealed that18F-FDG PET/CT was the independent predictive factor of two-year PFS for patients with HL/NHL (P<0.01). Conclusion:After four or six cycles of chemotherapy, PET/CT is found to be an independent predictor of PFS in HL/NHL. there are significant values in its treatment directing and prognosis assessing in the malignant lymphoma.